• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.

作者信息

Willett Christopher G, Boucher Yves, Duda Dan G, di Tomaso Emmanuelle, Munn Lance L, Tong Ricky T, Kozin Sergey V, Petit Lucine, Jain Rakesh K, Chung Daniel C, Sahani Dushyant V, Kalva Sanjeeva P, Cohen Kenneth S, Scadden David T, Fischman Alan J, Clark Jeffrey W, Ryan David P, Zhu Andrew X, Blaszkowsky Lawrence S, Shellito Paul C, Mino-Kenudson Mari, Lauwers Gregory Y

出版信息

J Clin Oncol. 2005 Nov 1;23(31):8136-9. doi: 10.1200/JCO.2005.02.5635.

DOI:10.1200/JCO.2005.02.5635
PMID:16258121
Abstract
摘要

相似文献

1
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.抗血管生成治疗的替代标志物以及贝伐单抗联合放疗和化疗的剂量限制性毒性：直肠癌患者I期试验的持续经验
J Clin Oncol. 2005 Nov 1;23(31):8136-9. doi: 10.1200/JCO.2005.02.5635.
2
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.贝伐单抗、奥沙利铂和卡培他滨联合放疗用于直肠癌：I期试验结果。
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8. doi: 10.1016/j.ijrobp.2007.02.001.
3
Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.贝伐珠单抗、卡培他滨、氨磷汀和术前低分割加速放疗（HypoArc）治疗直肠癌：一项 II 期研究。
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):492-8. doi: 10.1016/j.ijrobp.2010.02.037. Epub 2010 Jun 30.
4
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.贝伐珠单抗、奥沙利铂、氟尿嘧啶和放疗治疗直肠癌。
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):124-9. doi: 10.1016/j.ijrobp.2010.08.005. Epub 2010 Oct 13.
5
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.一项关于在氟尿嘧啶和羟基脲基础上的同步放化疗中加入贝伐单抗用于预后不良头颈癌的I期研究。
J Clin Oncol. 2008 Apr 1;26(10):1732-41. doi: 10.1200/JCO.2007.13.1706.
6
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.西妥昔单抗联合卡培他滨、每周一次伊立替康及放疗作为直肠癌新辅助治疗的I期试验
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1384-90. doi: 10.1016/j.ijrobp.2006.07.005. Epub 2006 Sep 18.
7
Combined cetuximab, capecitabine, oxaliplatin, and radiotherapy in rectal cancer: Dr. Jekyll or Mr. Hyde? In regard to Rödel et al. (Int J Radiat Oncol Biol Phys 2008;70:1081-1086.).西妥昔单抗、卡培他滨、奥沙利铂联合放疗用于直肠癌：是化身博士还是海德先生？关于勒德尔等人的研究（《国际放射肿瘤学、生物学、物理学杂志》2008年；70：1081 - 1086） 。
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):959-60; author reply 960. doi: 10.1016/j.ijrobp.2008.02.027.
8
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?抑制血管生成途径能否提高基于静脉注射5-氟尿嘧啶方案的疗效？
Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S69-73. doi: 10.3816/ccc.2004.s.011.
9
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer.一项新辅助贝伐珠单抗联合卡培他滨和同期放疗治疗局部进展期直肠癌的 II 期研究。
Angiogenesis. 2012 Mar;15(1):141-50. doi: 10.1007/s10456-011-9250-0. Epub 2012 Jan 3.
10
Combined-modality therapy for rectal cancer: future prospects.直肠癌的综合治疗：未来前景
Clin Colorectal Cancer. 2007 Sep;6(9):625-33. doi: 10.3816/CCC.2007.n.030.

引用本文的文献

1
Plasma and serum concentrations of VEGF-A121, but not of VEGF-A165, increase post-bevacizumab administration.贝伐单抗给药后，血浆和血清中VEGF - A121的浓度升高，而VEGF - A165的浓度未升高。
PLoS One. 2024 Dec 19;19(12):e0316035. doi: 10.1371/journal.pone.0316035. eCollection 2024.
2
Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior.尼达尼布和抗血管生成药物对葡萄膜黑色素瘤细胞行为的影响。
Invest Ophthalmol Vis Sci. 2024 Feb 1;65(2):30. doi: 10.1167/iovs.65.2.30.
3
PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma.
PD-L1 阳性循环内皮祖细胞与头颈部鳞状细胞癌患者对 PD-1 阻断的免疫反应相关。
Cancer Immunol Immunother. 2024 Jan 4;73(1):3. doi: 10.1007/s00262-023-03595-0.
4
Pathological angiogenesis: mechanisms and therapeutic strategies.病理性血管生成：机制与治疗策略。
Angiogenesis. 2023 Aug;26(3):313-347. doi: 10.1007/s10456-023-09876-7. Epub 2023 Apr 15.
5
Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8T cells.低剂量抗 VEGFR2 治疗通过下调肿瘤浸润 CD8T 细胞上 layilin 的表达促进肺腺癌中的抗肿瘤免疫。
Cell Oncol (Dordr). 2022 Dec;45(6):1297-1309. doi: 10.1007/s13402-022-00718-0. Epub 2022 Oct 19.
6
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.血管内皮生长因子/血管内皮生长因子受体在癌症治疗中的分子机制及未来意义。
Clin Cancer Res. 2023 Jan 4;29(1):30-39. doi: 10.1158/1078-0432.CCR-22-1366.
7
Exercise Training Effects on Circulating Endothelial and Progenitor Cells in Heart Failure.运动训练对心力衰竭患者循环内皮细胞和祖细胞的影响。
J Cardiovasc Dev Dis. 2022 Jul 10;9(7):222. doi: 10.3390/jcdd9070222.
8
Role of vascular endothelial growth factor in radiotherapy resistance to esophageal squamous cell carcinoma.血管内皮生长因子在食管鳞癌放射抗拒中的作用。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2543-2550. doi: 10.1007/s00432-022-04122-x. Epub 2022 Jun 29.
9
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia.系统使用贝伐珠单抗以促进抗磷脂综合征和胃肠道血管发育不良出血的抗凝。
J Thromb Thrombolysis. 2022 Apr;53(3):708-711. doi: 10.1007/s11239-021-02590-5. Epub 2021 Oct 25.
10
Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome.系统性贝伐珠单抗治疗 Heyde 综合征难治性出血和输血依赖型贫血。
Blood Adv. 2021 Oct 12;5(19):3850-3854. doi: 10.1182/bloodadvances.2021004810.